Have questions?Contact Us
Fatty Liver – NASH
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
NASH is an acronym that stands for Non-Alcoholic SteatoHepatitis. It is the most severe form of non-alcoholic fatty liver disease (NAFLD), and is characterized by the presence of an abnormal accumulation of fat in the liver. It is heavily influenced by lifestyle; risk factors include: high blood pressure, obesity, type 2 diabetes, high cholesterol, insulin resistance, and metabolic syndrome. It may lead to complications such as cirrhosis and liver cancer. The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH.
Eligibility and Recruitment Information
|Inclusion||NASH (Non-alcoholic Steatohepatitis), BMI above 27, elevated liver enzymes, and MRI compatible|
|Exclusion||Cancer in the past 5 years, gastric surgery, cirrhosis, or heart issues|
|Location||Orlando, FL, The Villages, FL|